Cargando…

Switching From Glargine to Degludec: The Effect on Metabolic Control and Safety During 1-Year of Real Clinical Practice in Children and Adolescents With Type 1 Diabetes

Background/Objective: Insulin degludec (IDeg) is an ultra-long-acting analog with less daily variability compared to other basal insulins. In this retrospective study we examined 1-year efficacy and safety of IDeg in youth with type 1 diabetes (T1D). Subjects/Methods: Thirty-seven patients [11.7 ± 4...

Descripción completa

Detalles Bibliográficos
Autores principales:	Predieri, Barbara, Suprani, Tosca, Maltoni, Giulio, Graziani, Vanna, Bruzzi, Patrizia, Zucchini, Stefano, Iughetti, Lorenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6115523/ https://www.ncbi.nlm.nih.gov/pubmed/30190702 http://dx.doi.org/10.3389/fendo.2018.00462

Ejemplares similares

Improved Cardiovascular and Cardiometabolic Risk in Patients With Type 1 Diabetes and Autoimmune Polyglandular Syndrome Switched From Glargine to Degludec Due to Hypoglycaemic Variability
por: Guarnotta, Valentina, et al.
Publicado: (2018)

Glycemic Control Improvement in Italian Children and Adolescents With Type 1 Diabetes Followed Through Telemedicine During Lockdown Due to the COVID-19 Pandemic
por: Predieri, Barbara, et al.
Publicado: (2020)

The impact of BMI on long-term anthropometric and metabolic outcomes in girls with idiopathic central precocious puberty treated with GnRHas
por: Bruzzi, Patrizia, et al.
Publicado: (2022)

Effects of Switching from Insulin Glargine or Detemir to Insulin Degludec in Patients with Type 1 Diabetes Mellitus
por: Kusunoki, Yoshiki, et al.
Publicado: (2013)

Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Yang, Yunjiao, et al.
Publicado: (2022)

Obesity in patients with acute lymphoblastic leukemia in childhood
por: Iughetti, Lorenzo, et al.
Publicado: (2012)

Longitudinal evaluation of endothelial markers in children and adolescents with familial hypercholesterolemia
por: Bruzzi, Patrizia, et al.
Publicado: (2021)

Endocrine Disrupting Chemicals and Type 1 Diabetes
por: Predieri, Barbara, et al.
Publicado: (2020)

COVID-19 and Type 1 Diabetes: Concerns and Challenges
por: Trevisani, Viola, et al.
Publicado: (2020)

Glargine and degludec: Solution behaviour of higher dose synthetic insulins
por: Adams, Gary G., et al.
Publicado: (2017)

Safety and Efficacy of Long-Acting Insulins Degludec and Glargine Among Asian Patients With Type 2 Diabetes Mellitus: A Meta-Analysis
por: Kant, Ravi, et al.
Publicado: (2021)

Improved health status with insulin degludec compared with insulin glargine in people with Type 1 diabetes
por: Home, P D, et al.
Publicado: (2012)

High Levels of Perfluorooctane Sulfonate in Children at the Onset of Diabetes
por: Predieri, Barbara, et al.
Publicado: (2015)

Unusual presentation of Rosai-Dorfman disease in a 14-month-old Italian child: a case report and review of the literature
por: di Dio, Francesco, et al.
Publicado: (2016)

Isolated hypoaldosteronism as first sign of X-linked adrenal hypoplasia congenita caused by a novel mutation in NR0B1/DAX-1 gene: a case report
por: Iughetti, Lorenzo, et al.
Publicado: (2019)

A 1‐year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal–bolus insulin therapy (Kumamoto Insulin Degludec Observational study)
por: Shimoda, Seiya, et al.
Publicado: (2016)

Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus
por: Evans, Marc, et al.
Publicado: (2017)

Editorial: Clinical aspects of different forms of diabetes in children and adolescents
por: Zucchini, Stefano
Publicado: (2022)

Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function
por: Hartmann, Thorsten, et al.
Publicado: (2016)

The Silent Epidemic of Diabetic Ketoacidosis at Diagnosis of Type 1 Diabetes in Children and Adolescents in Italy During the COVID-19 Pandemic in 2020
por: Cherubini, Valentino, et al.
Publicado: (2022)

Comparative Effectiveness of Switching From First-Generation Basal Insulin to Glargine 300 U/ml or Degludec 100 U/ml in Type 1 Diabetes: The RESTORE-1 Study
por: Laviola, Luigi, et al.
Publicado: (2020)

Comparative clinical outcomes of insulin degludec and insulin glargine 300 U/mL after switching from other basal insulins in real‐world patients with type 1 and type 2 diabetes
por: Oya, Junko, et al.
Publicado: (2021)

Corrigendum: The silent epidemic of diabetic ketoacidosis at diagnosis of type 1 diabetes in children and adolescents in italy during the covid-19 pandemic in 2020
por: Cherubini, Valentino, et al.
Publicado: (2022)

Glycemic Variability in Type 1 Diabetes Compared with Degludec and Glargine on the Morning Injection: An Open-label Randomized Controlled Trial
por: Iga, Ryo, et al.
Publicado: (2017)

Insulin doses requirements in patients with type 1 diabetes using glargine U300 or degludec in routine clinical practice
por: Carral San Laureano, Florentino, et al.
Publicado: (2021)

Cost-minimization analysis of degludec/liraglutide versus glargine/aspart: economic implications of the DUAL VII study outcomes
por: Torre, Enrico, et al.
Publicado: (2018)

Obesity and craniopharyngioma
por: Iughetti, Lorenzo, et al.
Publicado: (2011)

Glycemic Control in Kenyan Children and Adolescents with Type 1 Diabetes Mellitus
por: Ngwiri, Thomas, et al.
Publicado: (2015)

Final height and body mass index in adult survivors of childhood acute lymphoblastic leukemia treated without cranial radiotherapy: a retrospective longitudinal multicenter Italian study
por: Bruzzi, Patrizia, et al.
Publicado: (2014)

Effect of Insulin Degludec Versus Insulin Glargine U100 on Hypoglycemia in Hispanic Patients With Type 2 Diabetes: Results From the SWITCH 2 Trial
por: Chaykin, Louis, et al.
Publicado: (2019)

Diabetes and Prediabetes in Children With Cystic Fibrosis: A Systematic Review of the Literature and Recommendations of the Italian Society for Pediatric Endocrinology and Diabetes (ISPED)
por: Mozzillo, Enza, et al.
Publicado: (2021)

Effects of dulaglutide combined with insulin degludec on glucose fluctuations and appetite in type 2 diabetes
por: Huang, Jinxin, et al.
Publicado: (2023)

Insulin degludec does not increase antibody formation versus insulin glargine: an evaluation of phase IIIa trials
por: Vora, J., et al.
Publicado: (2016)

Expert Opinion on the Management of Growth Hormone Deficiency in Brain Tumor Survivors: Results From an Italian Survey
por: Di Iorgi, Natascia, et al.
Publicado: (2022)

Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2
por: Heller, Simon R., et al.
Publicado: (2019)

Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U100 in Patients with Type 1 and Type 2 Diabetes Mellitus in Serbia
por: Lalić, Nebojša, et al.
Publicado: (2018)

Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria
por: Russel-Szymczyk, Monika, et al.
Publicado: (2019)

Insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
por: Buscemi, Silvio, et al.
Publicado: (2019)

Perinatal and postnatal exposure to phthalates and early neurodevelopment at 6 months in healthy infants born at term
por: Lucaccioni, Laura, et al.
Publicado: (2023)

Specific miRNAs Change After 3 Months of GH treatment and Contribute to Explain the Growth Response After 12 Months
por: Catellani, Cecilia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ig71rleunti3bbanpi2qaafj7l